Literature DB >> 6800827

Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test.

H Wietholtz, M Voegelin, M J Arnaud, J Bircher, R Preisig.   

Abstract

[1-Methyl-14C], [3-Methyl-14C] and [7-Methyl-14C] caffeine were used to investigate demethylation in control rats, and in rats pretreated with phenobarbital or 3-methylcholanthrene, by a 14CO2-exhalation test. Compared to controls, pretreatment with phenobarbital did not enhance demethylation of any of the labelled caffeines. In contrast, induction by 3-methylcholanthrene, presumably of cytochrome P-448, resulted in highly significant increases in peak 14CO2 exhalation rates, 14CO2 disappearance constants and areas under the exhalation rate - time curves. Based on these results, [7-methyl-14C] and [3-methyl-14C] caffeine were chosen for assessing the feasibility of a caffeine breath test in man, using 5 normal volunteers and 2 patients with compensated liver cirrhosis. 14CO2 exhalation curves in cirrhotics were clearly different from those in normal volunteers, being characterised by a slower rise and a lower specific activity of exhaled 14CO2. Since the variability of the levels of the specific activity in subjects with normal livers suggested the influence of extraneous factors, a second group of normal volunteers, smokers and nonsmokers, was investigated. With either labels, the average 14CO2 exhalation rate was doubled in smokers. From these studies in rats and preliminary results in man it is concluded that specifically labelled caffeine is a suitable and promising substrate for studying demethylation by breath analysis. Presumably, caffeine represents a safe and sensitive indicator of the activity of the cytochrome P-448 system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800827     DOI: 10.1007/BF00609588

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

2.  Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene.

Authors:  A Aldridge; W D Parsons; A H Neims
Journal:  Life Sci       Date:  1977-10-01       Impact factor: 5.037

Review 3.  Environmental hepatic injury in man.

Authors:  H Popper; M A Gerber; F Schaffner; I J Selikoff
Journal:  Prog Liver Dis       Date:  1979

4.  Effect of Aroclor 1254, phenobarbital, and polycyclic aromatic hydrocarbons on the plasma clearance of caffeine in the rat.

Authors:  R M Welch; S Y Hsu; R L DeAngelis
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat.

Authors:  B H Lauterburg; J Bircher
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

6.  Identification, kinetic and quantitative study of [2-14C] and [1-Me-14C]caffeine metabolites in rat's urine by chromatographic separations.

Authors:  M J Arnaud
Journal:  Biochem Med       Date:  1976-08

7.  The induction of liver microsomal proteins by 3-methylcholanthrene in rats of different age, sex and strain.

Authors:  P R McIntosh; A C Peacock; H V Gelboin
Journal:  Biochim Biophys Acta       Date:  1980-02-07

8.  Aryl hydrocarbon hydroxylase activity in human placenta from cigarette smoking and nonsmoking women.

Authors:  D W Nebert; J Winker; H V Gelboin
Journal:  Cancer Res       Date:  1969-10       Impact factor: 12.701

9.  [The galactose breath test. Modification of the method and comparison with galactose elimination capacity and plasma disappearance of bromsulphatein (author's transl)].

Authors:  L Grimm; J Bircher; R Preisig
Journal:  Z Gastroenterol       Date:  1980-01       Impact factor: 2.000

10.  Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease.

Authors:  J F Schneider; A L Baker; N W Haines; G Hatfield; J L Boyer
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

View more
  17 in total

1.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Authors:  M A Butler; M Iwasaki; F P Guengerich; F F Kadlubar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

4.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  Comparison of the urinary metabolite profile of caffeine in young and elderly males.

Authors:  J Blanchard; S J Sawers; J H Jonkman; D D Tang-Liu
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 6.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

7.  Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.

Authors:  D R Abernethy; E L Todd
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

9.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Comparative pharmacokinetics of caffeine in young and elderly men.

Authors:  J Blanchard; S J Sawers
Journal:  J Pharmacokinet Biopharm       Date:  1983-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.